Abzena & Sartorius Case Study: From Complexity to Clarity – Mapping ADC Mechanisms in Real Time

Unlock Mechanistic Clarity for Your ADC Program

Traditional in vitro assays tell you if your ADC works. But in today’s competitive and increasingly regulated landscape, you need to know how — and that distinction can make or break a development program.

In this case study, Abzena scientists partnered with Sartorius to demonstrate how an integrated live-cell imaging approach, using the Incucyte® Live-Cell Analysis System, can resolve payload-driven killing, immune-mediated cytotoxicity, and bystander effects within a single, scalable experiment — no separate assays required.

Using Kadcyla and Enhertu as benchmarks, the team profiled two clinically validated ADCs against mixed Her2+ and Her2- tumor spheroids across multiple concentrations, effector-to-target ratios, and PBMC donors. The result? Rich, kinetic data that mirrors real clinical treatment selection patterns and surfaces mechanistic differences that conventional endpoints simply miss.

Download the case study to discover:

• How 3D tumor-immune co-cultures reveal overlapping ADC mechanisms in real time
• Why Kadcyla and Enhertu show fundamentally distinct pharmacological profiles — and what that means for your program
• How a single integrated assay can generate decision-ready data to de-risk early-stage candidate selection

Whether you’re profiling a novel ADC or stress-testing your lead candidate, Abzena’s bioassay expertise can help you move from complexity to clarity — faster.

Download the Case Study